Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0229
EDITORIAL
|
Tumor diversity: Implementing NGS into clinic
|
|
Affiliation: William CS Cho, Scientific Officer, Department of Clinical Oncology, Queen Elizabeth Hospital, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong.
E-mail: williamcscho@gmail.com ; chocs@ha.org.hk |
Abstract
The hypothesis of genetic and genomic diversity in malignant tumors is now confirmed by recent studies using next-generation sequencing (NGS) technologies. Heterogeneity is now assessed not only among different breast cancer patients with same tumor type, stage and conventional clinicopathologic features but also for individual renal cancer patients with substantial differences in mutational landscape when NGS0based sequencing of distinct separate biopsies from the same tumor. These findings published over the last few months in Nature and NEJM may change the way of anticancer drugs selection and decision-making by multidisciplinary teams with expertise in analysis and interpretation of genomic data in clinical genomic medicine era. Here I discuss potential diagnostic, prognostic and therapeutic applications and challenges of genome sequence in patients with solid cancer.
(Citation: Gastric & Breast Cancer 2012; 11(3): 121-126)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 27 June 2012 |
|
